UCFA
AKBA icon

United Capital Financial Advisors’s Akebia Therapeutics AKBA Stock Holding History

United Capital Financial Advisors’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-10,299
Closed -$5.97K – 966
2022
Q4 		$5.97K Hold
10,299
– – ﹤0.01% 1033
2022
Q3 		$3K Hold
10,299
– – ﹤0.01% 1082
2022
Q2 		$4K Hold
10,299
– – ﹤0.01% 1118
2022
Q1 		$7K Buy
+10,299
New +$22K ﹤0.01% 1158

Other funds holding AKBA

AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
MFS
Mirabella Financial Services London, United Kingdom $1.06B AUM 19.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

United Capital Financial Advisors's AKBA Position: Q1 2023 in Review

United Capital Financial Advisors sold out of Akebia Therapeutics (AKBA) in Q1 2023, closing a stake of 10,299 shares — an estimated $5.97K sold.

United Capital Financial Advisors first reported a position in AKBA in Q1 2022 and held it in 4 quarters. The position peaked at $7K in Q1 2022. 65 funds tracked by Wall St. Rank hold AKBA as of Q1 2023.

  • United Capital Financial Advisors reported no remaining Akebia Therapeutics position as of Q1 2023 after selling out during the quarter.
  • United Capital Financial Advisors sold 10,299 Akebia Therapeutics shares in Q1 2023, an estimated $5.97K.
  • United Capital Financial Advisors first reported a position in Akebia Therapeutics in Q1 2022 and held it in 4 quarters.
  • United Capital Financial Advisors's Akebia Therapeutics position peaked at $7K in Q1 2022.
  • 65 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2023.

Based on United Capital Financial Advisors's 13F filing for Q1 2023, filed 15 May 2023.